Tirzepatide 15mg

Tirzepatide is a 39-amino-acid synthetic peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both incretin pathways simultaneously, it has been investigated for its effects on insulin secretion, glucagon suppression, gastric emptying and energy homeostasis, and is one of the most-studied dual incretin agonists in modern metabolic research.

This 15mg lyophilised peptide vial is supplied for reconstitution with bacteriostatic water and is well suited to pilot studies, dose-ranging work and short in vitro or ex vivo protocols where a smaller quantity of high-purity material is preferred over a bulk format.

Research Applications • Investigation of dual GLP-1/GIP receptor signalling and incretin crosstalk • Studies on insulin secretion, glucagon suppression and glycaemic regulation • Models of body-weight regulation, adiposity and energy expenditure • Comparative incretin pharmacology against single-agonist reference peptides

Specification • Identity: Tirzepatide (CAS 2023788-19-2) • Molecular weight: 4813.52 g/mol • Purity: 99.5%+ verified by HPLC and Mass Spectrometry • Format: lyophilised peptide vial — reconstitute with bacteriostatic water before use • Storage: store lyophilised at -20°C; once reconstituted, refrigerate at 2-8°C and use within 4-6 weeks; protect from light

For research use only — not for human consumption.